West Pharmaceutical Services vs Dentsply Sirona
WST and XRAY side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How WST and XRAY compare
West Pharmaceutical Services is the larger company, worth 15 times as much as Dentsply Sirona ($29.0B against $1.9B).
West Pharmaceutical Services grew revenue faster over the last twelve months (12.6% versus −0.76% for Dentsply Sirona).
West Pharmaceutical Services keeps more of each dollar of sales as profit, with a net margin of 18.8% compared with −15.0% at Dentsply Sirona.
Both pay dividends: West Pharmaceutical Services yields 0.21% and Dentsply Sirona 1.7%.
West Pharmaceutical Services scores higher on the StockData Score (20 against 9 for Dentsply Sirona), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | WST | XRAY |
|---|---|---|
| Size and price | ||
| Market cap | $29.0B | $1.9B |
| Share price | $412.62 | $9.53 |
| Change, 1 year | 44.9% | −25.9% |
| Change, 5 years | 2.2% | −82.9% |
| Beta (5Y) | 1.05 | 0.90 |
| Employees | 11K | 14K |
| StockData Score | ||
| Total score | 20 (better) | 9 |
| Valuation score | 1 | 3 (better) |
| Growth score | 4 (better) | 0 |
| Performance score | 5 (better) | 2 |
| Health score | 6 (better) | 1 |
| Dividend score | 4 (better) | 3 |
| Valuation | ||
| P/E | 46.3× | – |
| P/S | 8.5× | 0.5× (better) |
| P/B | 9.8× | 1.4× (better) |
| EV/EBITDA | 29.8× (better) | 99.6× |
| P/FCF | 64.0× | 13.3× (better) |
| FCF yield | 1.6% | 7.5% (better) |
| Fair value | $314.51 | $20.33 |
| Margin of safety | −31.2% | 53.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 12.6% (better) | −0.76% |
| Revenue growth, 5Y average | 7.4% (better) | 2.0% |
| Net income growth (TTM) | 29.9% | – |
| EPS growth (TTM) | 32.2% | – |
| EPS growth, 5Y average | 8.2% | – |
| Profitability | ||
| Gross margin | 37.6% | 49.5% (better) |
| Operating margin | 23.0% (better) | −8.5% |
| Net margin | 18.8% (better) | −15.0% |
| FCF margin | 13.3% (better) | 3.9% |
| Return on equity | 21.2% (better) | −33.0% |
| Return on invested capital | 23.0% (better) | −6.7% |
| Financial health | ||
| Debt / equity | 0.07 (better) | 1.65 |
| Net debt / EBITDA | −0.27 | 50.90 (better) |
| Interest coverage | 96.3× (better) | −3.4× |
| Current ratio | 2.82 (better) | 1.63 |
| Altman Z-score | 19.43 (better) | 0.56 |
| Piotroski F-score | 8 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | 0.21% | 1.7% (better) |
| Payout ratio | 9.8% | – |
| Years of dividend growth | 16 (better) | 0 |
| Dividend growth, 5Y average | 5.4% | 9.9% (better) |
| Buyback yield | 2.4% | – |
| Shareholder yield | 2.6% (better) | 1.7% |
| Ownership | ||
| Held by institutions | 100% | 114% |
| Held by insiders | 0.66% | 0.87% |
| Insider net buying, 12 months | −$6.6M | $826K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 3.0% | 12.9% |
Go deeper
- WST stock overview
- WST income statement
- WST valuation and score
- XRAY stock overview
- XRAY income statement
- XRAY valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.